Aakriti G Shukla1, Portia E Sirinek1, C Gustavo De Moraes1, Dana M Blumberg1, George A Cioffi1, Alon Skaat2, Christopher A Girkin3, Robert N Weinreb4, Linda M Zangwill4, Donald C Hood5, Jeffrey M Liebmann1. 1. Bernard and Shirlee Brown Glaucoma Research Laboratory, Columbia University Medical Center, Edward S. Harkness Eye Institute. 2. Goldschleger Eye Institute, Sheba Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 3. School of Medicine, University of Alabama, Birmingham, AL. 4. Hamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, CA. 5. Departments of Psychology and Ophthalmology, Columbia University, New York, NY.
Abstract
PRECIS: In this prospective cohort study, disc hemorrhages were associated with more severe central damage on 24-2 and 10-2 visual fields (VFs), and faster progression globally on 24-2 VFs and centrally on 10-2 VFs. PURPOSE: To study the relationship between disc hemorrhage (DH) and the presence and progression of glaucomatous central VF damage. METHODS: Cross-sectional and longitudinal analyses were performed on data from the African Descent and Glaucoma Evaluation Study (ADAGES) cohort. Two masked investigators reviewed disc photographs for the presence and location of DH. 24-2 central VF damage was based on the number of test locations within the central 10 degrees of the 24-2 field pattern deviation and their mean total deviation (MTD). 10-2 central VF damage was based on pattern deviation and MTD. Main outcome measures were the association between DH and presence of central VF damage and between DH and worsening of VF. RESULTS: DH was detected in 21 of 335 eyes (6.2%). In the cross-sectional analysis, DH was significantly associated with more severe central damage on 24-2 [incidence rate ratio=1.47; 95% confidence interval (CI)=1.02-2.12; P=0.035] and 10-2 VFs (incidence rate ratio=1.81; 95% CI=1.26-2.60; P=0.001). In the longitudinal analysis, DH eyes progressed faster than non-DH eyes based on 24-2 global MTD rates (difference in slopes, β=-0.06; 95% CI=-0.11 to -0.01; P=0.009) and 10-2 MTD rates (β=-0.10; 95% CI=-0.14 to -0.06; P< 0.001), but not 24-2 central MTD rates (β=-0.02; 95% CI=-0.078 to 0.026; P=0.338). CONCLUSION: DH was associated with the presence and progression of central VF defects. DH identification should prompt intensive central VF monitoring and surveillance with 10-2 fields to detect progression.
PRECIS: In this prospective cohort study, disc hemorrhages were associated with more severe central damage on 24-2 and 10-2 visual fields (VFs), and faster progression globally on 24-2 VFs and centrally on 10-2 VFs. PURPOSE: To study the relationship between disc hemorrhage (DH) and the presence and progression of glaucomatous central VF damage. METHODS: Cross-sectional and longitudinal analyses were performed on data from the African Descent and Glaucoma Evaluation Study (ADAGES) cohort. Two masked investigators reviewed disc photographs for the presence and location of DH. 24-2 central VF damage was based on the number of test locations within the central 10 degrees of the 24-2 field pattern deviation and their mean total deviation (MTD). 10-2 central VF damage was based on pattern deviation and MTD. Main outcome measures were the association between DH and presence of central VF damage and between DH and worsening of VF. RESULTS:DH was detected in 21 of 335 eyes (6.2%). In the cross-sectional analysis, DH was significantly associated with more severe central damage on 24-2 [incidence rate ratio=1.47; 95% confidence interval (CI)=1.02-2.12; P=0.035] and 10-2 VFs (incidence rate ratio=1.81; 95% CI=1.26-2.60; P=0.001). In the longitudinal analysis, DH eyes progressed faster than non-DH eyes based on 24-2 global MTD rates (difference in slopes, β=-0.06; 95% CI=-0.11 to -0.01; P=0.009) and 10-2 MTD rates (β=-0.10; 95% CI=-0.14 to -0.06; P< 0.001), but not 24-2 central MTD rates (β=-0.02; 95% CI=-0.078 to 0.026; P=0.338). CONCLUSION:DH was associated with the presence and progression of central VF defects. DH identification should prompt intensive central VF monitoring and surveillance with 10-2 fields to detect progression.
Authors: Claude F Burgoyne; J Crawford Downs; Anthony J Bellezza; J-K Francis Suh; Richard T Hart Journal: Prog Retin Eye Res Date: 2005-01 Impact factor: 21.198
Authors: Jonathan C Chou; Clara C Cousins; John B Miller; Brian J Song; Lucy Q Shen; Michael A Kass; Janey L Wiggs; Louis R Pasquale Journal: Am J Ophthalmol Date: 2018-01-09 Impact factor: 5.258
Authors: Donald C Hood; Ali S Raza; Carlos Gustavo V de Moraes; Jeffrey G Odel; Vivienne C Greenstein; Jeffrey M Liebmann; Robert Ritch Journal: Invest Ophthalmol Vis Sci Date: 2011-02-16 Impact factor: 4.799
Authors: Dana M Blumberg; Carlos Gustavo De Moraes; Alisa J Prager; Qi Yu; Lama Al-Aswad; George A Cioffi; Jeffrey M Liebmann; Donald C Hood Journal: JAMA Ophthalmol Date: 2017-07-01 Impact factor: 7.389
Authors: Harsha L Rao; Shruthi Sreenivasaiah; Shivani Dixit; Mohammed Riyazuddin; Srilakshmi Dasari; Jayasree P Venugopal; Zia S Pradhan; Narendra K Puttaiah; Sathi Devi; Kaweh Mansouri; Carroll A B Webers; Robert N Weinreb Journal: J Glaucoma Date: 2019-03 Impact factor: 2.503
Authors: Omar S Faridi; Sung Chul Park; Rajiv Kabadi; Daniel Su; Carlos Gustavo De Moraes; Jeffrey M Liebmann; Robert Ritch Journal: Ophthalmology Date: 2014-03-31 Impact factor: 12.079
Authors: Xiongfei Liu; Alicia Lau; Huiyuan Hou; Sasan Moghimi; James A Proudfoot; Eric Chan; Jiun Do; Andrew Camp; Derek Welsbie; Carlos Gustavo de Moraes; Christopher A Girkin; Jeffrey M Liebmann; Robert N Weinreb Journal: Ophthalmol Glaucoma Date: 2021-01-30
Authors: Ryan Caezar C David; Sasan Moghimi; Jiun L Do; Huiyuan Hou; James Proudfoot; Linda M Zangwill; Alireza Kamalipour; Takashi Nishida; Carlos Gustavo De Moraes; Christopher A Girkin; Jeffrey M Liebmann; Robert N Weinreb Journal: Am J Ophthalmol Date: 2021-06-06 Impact factor: 5.488
Authors: Milica A Margeta; Kitiya Ratanawongphaibul; Edem Tsikata; Michele Zemplenyi; Courtney L Ondeck; Janice Kim; Anne L Coleman; Fei Yu; Johannes F de Boer; Teresa C Chen Journal: Am J Ophthalmol Date: 2021-06-29 Impact factor: 5.258